
BO41843
NCT04546009
JCP084
A Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Status:
Recruiting

III
Phase

1st
Line of Therapy

Advanced / Metastatic
Disease Stage

Biomarker(s)
ER+, HER2-
Investigational
Product
GDC-9545
Selective estrogen receptor degrader (SERD) (p.o.)
Treatment Arms
o Experimental: GDC-9545 + Letrozole-matched Placebo + Palbociclib
o Active Comparator: Letrozole + GDC-9545-matched Placebo + Palbociclib